NEW YORK--(BUSINESS WIRE)--Citi’s Issuer Services, acting through Citibank, N.A., has been appointed as the depositary bank by I-Mab for its American Depositary Receipt (ADR) program. I-Mab is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
I-Mab’s program was established in connection with a $103,703,600 initial public offering of its ADRs (exclusive of the over-allotment option), priced at $14.00 per ADR. The ADRs are listed on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADRs represent 23 ordinary shares of I-Mab.
“Citi is proud to be selected as depositary bank for I-Mab’s ADR program,” said Dirk Jones, Head of Global Issuer Services at Citi. “Citi is committed to providing I-Mab and its investors with the highest quality ADR services.”
Citi is a leading provider of depositary receipt services. With depositary receipt programs in 61 markets, spanning equity and fixed-income products, Citi leverages its global network to provide cross-border capital market access to issuers, intermediaries and investors.
For more information about Citi’s Depositary Receipt Services, please visit www.citi.com/dr.
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.
Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi